A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » IAS 2011

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

July 19, 2011

HIV Integrase Inhibitor Dolutegravir Showing Well in First-Time Treatment Takers

by Tim Horn

ViiV Healthcare’s experimental integrase inhibitor dolutegravir (S/GSK-572), using the highest dose studied in the SPRING-1 clinical trial, was at least as effective as efavirenz (found in Sustiva and Atripla) in controlling HIV levels with fewer side effects over 48 weeks. These data from the study involving first-time HIV treatment takers were presented Tuesday, July 19, at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Rome.

Although the current crop of recommended antiretroviral (ARV) drugs is quite potent, each drug has its disadvantages. Some have troublesome side effects, while others must be taken several times a day. Needless to say, there’s a demand for new treatments that can be easily joined with other drugs into a single pill that can be taken once daily and that has minimal side effects.

One candidate with the potential to meet all of those challenges in dolutegravir. It is a second-generation integrase inhibitor that can be taken once daily, without the need for blood-level boosting by Norvir (ritonavir), and that so far appears to have minimal side effects. What’s more, the daily dose is small enough that it should be easy to combine with other drugs into a single pill—a prospect that is currently being explored, in the forum of 572-Trii.

To determine dolutegravir’s efficacy in people who hadn’t taken ARV therapy before, Jan van Lunzen, MD, from the University Medical Center in Hamburg-Eppendorf, Germany, and his colleagues randomized 205 people to take either an efavirenz plus either Truvada (tenofovir plus emtricitabine) or Epzicom (abacavir plus lamivudine), or Truvada/Epzicom plus one of three potential doses of dolutegravir: 10 milligrams (mg), 25 mg or 50 mg. The participants in the study were mostly white males, their average age was about 37, and their average CD4 count was 324.

During the first three months of the study, all doses of dolutegravir reduced viral loads to levels below 50 copies—undetectable—more effectively than Sustiva, which isn't uncommon among integrase inhibitors. Whereas more than 90 percent of those receiving dolutegravir had undetectable viral loads by the 146h week of treatment, less than 60 percent of those in the Sustiva group had achieved this early milestone.

After 48 weeks of treatment, undetectable viral load rates in the four groups were comparable. The percentage of people with viral loads less than 50 copies at 48 weeks was 91 percent with the 10 mg dose, 88 percent with the 25 mg dose and 90 percent with the 50 mg dose. Among those receiving Sustiva, 82 percent had viral loads below 50 copies after 48 weeks.

Significant increases in CD4 counts were reported in all study groups through 48 weeks of treatment. 

There were three study-defined virologic failures among the 150 patients receiving dolutegravir. Two occurred in the 10 mg group, and one occurred in the 25 mg group. No HIV mutations known to confer resistance to integrase inhibitors was documented in any of the patients; only in one patient was there a reported mutation associated with resistance to emtricitabine and lamivudine.

No patients in the 50 mg dolutegravir group had a confirmed viral load above 400 copies through week 48 of the study.

About 20 percent of volunteers receiving Sustiva, compared with 8 percent of those receiving dolutegravir, experienced moderate-to-severe side effects in the study. Gastrointestinal problems, central nervous system irregularities and skin rash appeared to be more common among those taking Sustiva.

Side effects leading to withdrawal from the study or a change in ARV therapy occurred in 8 percent of those in the Sustiva group, compared with 1 percent of those in the combined dolutegravir groups.

Severe lab abnormalities were rare, occurring in 12 percent of those receiving dolutegravir and 14 percent of those taking Sustiva. However, small changes in serum creatinine—a component of muscle and indicator of kidney function—were reported among those taking dolutegravir. This is likely because dolutegravir inhibits a component of the kidneys response for excreting creatinine, which is similar to at least two approved drugs: the antibiotic trimethoprim and the acid reflux medication cimetidine.

Patients treated with Sustiva were significantly more likely to experience increases in total cholesterol and “good” HDL cholesterol; of note, "bad" choleserol levels rose by 0.55 mg/dL in the dolutegravir group, compared with an average 15.9 mg/dL increase in the Sustiva group. And while average triglyceride levels tended to drop by 10 points among those taking dolutegravir, they increased by more than 10 points among those taking Sustiva.  

“In conclusion,” van Luzen reported, “dolutegravir administered once-daily without a booster showed a rapid and sustained response at all doses through week 48, with no integrase inhibitor mutations detected through 48 weeks.” He added that dolutegravir was well tolerated with fewer discontinuations than Sustiva, and with less pronounced effects of lipid levels.

The study will continue, as planned, for another 48 weeks. Studies involving treatment-experienced people living with HIV are also ongoing.

Search: dolutegravir, S/GSK-572, integrase, SPRING-1, ViiV, treatment naive, van Luzen, IAS, Rome


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    Hillcrester
    Ramona
    California


    Sloan1
    Dallas
    Texas


    cortaza100
    Oakland
    California


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.